Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages 600-608

  Martin, George M ^a   Stockfleth, Eggert ^b  

^a Dermatology and Laser Center of Maui   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; PLACEBO;

ACTINIC KERATOSIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; APPLICATION SITE REACTION; BASAL CELL CARCINOMA; CREATININE BLOOD LEVEL; CRYOSURGERY; CRYOTHERAPY; DESQUAMATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY SKIN; EDEMA; ENZYME INHIBITION; EROSION; ERYTHEMA; GEL; HUMAN; IMMUNE DEFICIENCY; LIP DISEASE; MULTICENTER STUDY (TOPIC); OSTEOARTHRITIS; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRURITUS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN DISCOMFORT; SKIN EXFOLIATION; SKIN MANIFESTATION; TREATMENT RESPONSE; XEROSIS;

ADMINISTRATION, CUTANEOUS; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; GELS; HUMANS; KERATOSIS, ACTINIC;

EID: 84860891967     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):S4-S7. (Pubitemid 30481723)
2. Braakhuis BJM, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63(8):1727-1730. (Pubitemid 36460827)
3. Vatve M, Ortonne J-P, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol. 2007;157(suppl 2):21-24. (Pubitemid 350179625)
4. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146(1):94-100. (Pubitemid 34158414)
5. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709-713. (Pubitemid 34023642)
6. Solaraze [package insert] Melville, NY: PharmaDerm; April 2010.
7. Merk HF. Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol. 2007;46(1):12-18. (Pubitemid 46029719)
8. Rundhaug JE, Fischer SM. Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol. 2008;84(2):322-329. (Pubitemid 351424030)
9. Ulrich M, Stockfleth E. Field treatment of actinic keratoses - focus on COX-2-inhibitors. Actas Dermosifilliogr. 2009;100(suppl 2):55-58.
10. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis. 1998;19(5):723-729. (Pubitemid 28376760)
11. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: Implications for therapeutic approaches. Photochem Photobiol. 2002;76(1):73-80.
12. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60(5):1306-1311. (Pubitemid 30151999)
13. Tjiu J-W, Liao Y-H, Lin S-J, et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol. 2006;126(5):1143-1151.
14. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3(1):53-61. (Pubitemid 32201610)
15. Nijsten T, Colpaert CG, Vermeulen PB, et al. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol. 2004;151(4):837-845. (Pubitemid 39482118)
16. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):493-501.
17. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94(7):3336-3340. (Pubitemid 27157312)
18. Tjiu J-W, Chen J-S, Shun C-T, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2009;129(4):1016-1025.
19. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60(2):293-297. (Pubitemid 30070754)
20. Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol. 2005;53(6):966-972. (Pubitemid 41677321)
21. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebocontrolled trial. J Natl Cancer Inst. 2010;102(24):1835-1844.
22. Maltusch A, Röwert-Huber J, Matthies C, et al. Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis. J Dtsch Dermatol Ges. [published online ahead of print May 20, 2011]. doi: 10.1111/j.1610-0387.2011.07700.x.
23. Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156(suppl 3):25-33. (Pubitemid 46632508)
24. Fecker LF, Stockfleth E, Braun FK, et al. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol. 2010;130(8):2098-2109.
25. Dirschka T, Bierhoff E, Pflugfelder A, Garbe C. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol. 2010;24(3):258-263.
26. Seed MP, Brown JR, Freemantle CN, et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res. 1997;57(9):1625-1629. (Pubitemid 27199647)
27. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5(2):156-159.
28. Brown MB, Marriott C, Martin GP. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int J Tissue React. 1995;17(4):133-140. (Pubitemid 26048919)
29. Fariba I, Ali A, Hossein SA, et al. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: A randomized, double-blind, placebo controlled study. Indian J Dermatol, Venereol Leprol. 2006;72(5):346-349. (Pubitemid 44579162)
30. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44(1):40-43. (Pubitemid 36246421)
31. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, openlabel assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3(4):401-407.
32. Nelson C, Rigel D. Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: One-year evaluation. J Clin Aesthetic Dermatol. 2009;2(7):20-25.
33. Röwert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(suppl 3):8-12. (Pubitemid 46632512)
34. Pflugfelder A, Welter A, Leiter U, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hualuronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Vernereol. [published online ahead of print March 18, 2011. doi: 10.1111/j.1468-3083.2011.04005.x.
35. Lima GS, da Silva GF, Gomes AP, de Araújo LM, Salum FG. Diclofenac in hyaluronic acid gel: An alternative treatment for actinic cheilitis. J Appl Oral Sci. 2010;18(5):533-537.
36. Nelson CG, Spencer J, Nelson CG Jr. A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol. 2007;6(7):712-717.
37. Ulrich C, Forschner T, Ulrich M, et al. Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. Br J Dermatol. 2007;156(suppl 3):43-46. (Pubitemid 46632514)
38. Batra R, Sundararajan S, Sandramouli S. Topical diclofenac gel for the management of periocular actinic keratosis. Ophthal Plast Reconstr Surg. [published online ahead of print July 21, 2011].
39. Luedecke J, Ulrich C, Krueger-Corcoran D, Lange-Asschenfeldt B, Roewert-Huber J, Stockfleth E. Topical 3% diclofenac in a 2.5% hyaluronate base versus topical 5% 5-fluorouracil versus cryotherapy in patients with actinic keratoses. Presented at: European Academy of Dermatology and Venereology: October 7-11, 2009; Berlin, Germany.
40. Kose O, Koc E, Erbil AH, Caliskan E, Kurumlu Z. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatol Treat. 2008;19(3):159-163. (Pubitemid 351882995)
41. Akarsu S, Aktan Ş, Atahan A, et al. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. Clin Exp Dermatol. [published online ahead of print March 21, 2011]. doi: 10.1111/j.1365-2230.2010.03999.x.
42. Ulrich C, Hackethal M, Ulrich M, et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: A series of six cases. Br J Dermatol. 2007;156(suppl 3):40-42. (Pubitemid 46632515)
43. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20(4):1-7.
44. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008;7(7):669-673.
45. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatolog. 2009;34(1):33-35.
46. Van Der Geer S, Krekels GAM. Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. J Dermatol Treat. 2009;20(5):259-265.
47. Eberle J, Fecker LF, Forschner T, Ulrich C, Röwert-Huber J, Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol. 2007;156(suppl 3):18-24. (Pubitemid 46632507)
48. Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: A meta-analysis of the recent studies. Arch Dermatol Res. 2005;297(5):185-189. (Pubitemid 41618696)
49. Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. Journal of drugs in dermatology : JDD. 2006;5(2):167-173.
50. Nelson CG. Diclofenac gel in the treatment of actinic keratoses. Ther Clin Risk Management. 2011;7:207-2011.
51. Voltaren [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc; October 2009.
52. U.S. Food and Drug Administration. Safety: Voltaren gel (diclofenac sodium topical gel) 1% - hepatic effects labeling changes. fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical-Products/ ucm193047.htm. Updated December 5, 2009. Accessed September 27, 2011.
53. Alam CAS, Seed MP, Willoughby DA. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol. 1995;47(5):407-411.